Drugs / INX-315
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05735080 | Mar 2023 → Jul 2027 expected | hormone receptor-positive breast cancer, metastatic malignant neoplasm, ovarian cancer | Incyclix Bio | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INX-315 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05735080 ↗ |
| Action | Inhibit | “small molecule inhibitor of cyclin dependent kinase 2 (CDK2)” NCT05735080 ↗ |
| Modality | Small molecule | “developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2)” NCT05735080 ↗ |
| Target | CDK2 | “inhibitor of cyclin dependent kinase 2 (CDK2)” NCT05735080 ↗ |